Table 5.
Uptake of HIV-related services based on aggregated monthly health record data at two clinics that received organization-specific quality improvement meetings
| Pre-PEACHES 9/1/2023—11/30/2023 |
During PEACHES 12/1/2023—2/29/2024 |
Post-PEACHES 3/1/2024—5/30/2024 |
|
|---|---|---|---|
| Region 1 Clinic A (Tennessee) | |||
| STI Screening among Individual Patients* | |||
| Anorectal Samples/Total STI Samples | 8/33 (24.2%) | 12/31 (38.7%) | 20/55 (36.4%) |
| Oropharyngeal Samples/Total STI Samples | 30/33 (90.9%) | 30/31 (96.8%) | 50/55 (90.9%) |
| Urethral Samples/Total STI Samples | 23/33 (69.7%) | 26/31 (83.9%) | 43/55 (78.2%) |
| New PrEP Prescriptions/Total STI Samples | 5/33 (15.2%) | 6/31 (19.4%) | 3/55 (5.5%) |
| HIV Tests Ordered/Total Clinic Visits | 52/500 (10.4%) | 59/467 (12.6%) | 66/687 (9.6%) |
| Region 2 Clinic B (Mississippi) |
Pre-PEACHES 3/1/2024—5/30/2024 |
During PEACHES 6/1/2024—8/31/2024 |
Post-PEACHES 9/1/2024—11/30/2024 |
| STI Screening among Patients | |||
| Anorectal Patients/Total STI Patients | 92/182 (50.5%) | 94/224 (42.0%) | 75/204 (36.8%) |
| Oropharyngeal Patients/Total STI Patients | 157/182 (86.3%) | 180/224 (80.4%) | 171/204 (83.8%) |
| Urethral Patients/Total STI Patients | 165/182 (90.7%) | 200/224 (89.3%) | 191/204 (93.6%) |
| New PrEP Prescriptions/Total non-HIV Care Visits | 15/116 (12.9%) | 17/160 (10.6%) | 8/161 (5.0%) |
| HIV Tests/Total non-HIV Care Visits | 100/116 (86.2%) | 151/160 (94.4%) | 132/161 (82.0%) |
*Individual patients may be counted more than once across anorectal, oropharyngeal, urethral gonorrhea and Chlamydia screening; some individual patients may have repeated screening within the same period of time. On April 1, 2024, Title X funding arrived and allowed the clinic to pay for three-site testing unrelated to the study intervention